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Efficacy of single versus boost vaccination against
influenza virus in patients with multiple myeloma
Influenza infection can cause severe complications in
patients with multiple myeloma. There are no systematic
studies on the efficacy of influenza vaccines in patients
with MM. In a retrospective, single-center study we
assessed the immune response of MM patients to one and
two doses of a trivalent influenza vaccine. 
The secondary aim of the study was to correlate the
immune responses with disease-specific parameters and
anti-neoplastic treatment. While a single dose of influenza
vaccine resulted in seroprotection in 14.6% of MM
patients, the frequency of protective titers was more than
doubled (31.3%) after a second dose of the vaccine. 
There is increasing evidence that the immune response
to influenza vaccine in MM patients is mostly
insufficient.1-3 Protection against influenza is mediated by
virus-specific antibodies and depends on the humoral
immune response,4,5 which is impaired in patients with
MM. Preliminary data support the assumption that the
immune response can be improved by a second dose of
vaccine.6,7
During the season 2012/13, MM patients were offered
the seasonal influenza vaccination [(Optaflu®, Novartis,
Basel, Switzerland; a trivalent cell-culture-based influenza
vaccine, containing inactivated viral surface antigens of
influenza A(H1N1)pdm09, influenza A(H3N2), and
influenza B/Yamagata-lineage; hereafter referred to as
A(H1N1), A(H3N2) and B/Yamagata)] in our myeloma out-
patient clinic. Blood samples were taken before and 4
weeks after each vaccination. Patients were offered a sec-
ond dose of vaccine if they responded insufficiently to the
first vaccination but had not had any serious side effects.
Antibody titers were analyzed using the hemagglutination
inhibitory (HI) assay. HI titers <1:10, 1:10 to <1:40  and
≥1:40 were considered as negative, indicating immune
memory and protection, respectively. Seroconversion was
defined as having occurred in seronegative patients if the
titer achieved after vaccination was ≥1:40, and in seroposi-
tive patients if the ratio achieved was ≥4-fold. 
Apart from this intervention, diphtheria and tetanus (DT)
immunization titers were determined as recall parameters
using enzyme-linked immunoassays. DT titers between
0.1 and 1.0 IU/mL were considered as protective, titers >1
IU/mL as indicating long-term protection.
Forty-eight patients with smoldering myeloma and MM
stage I or higher who had been vaccinated in our myeloma
outpatient clinic during the season 2012/13 were included
in this study, which was approved by the Institutional
Review Board. 
The patients’ characteristics are summarized in Table 1.
Most of the patients had previously received intensive ther-
apies; only two patients had not been given any
chemotherapy before the first vaccination. Seventeen
patients were in complete or near complete remission at
the time of the first vaccination. 
Differences of HI titers between two time points
(before/after first vaccination, after first/after second vacci-
nation and before first/after second vaccination) were ana-
lyzed using the signed-rank Wilcoxon test. Seroconversion
and seroprotection rates were analyzed comparing the
times before, after first and after second vaccination by
pairwise McNemar test. The association between medical
history and response to vaccine was examined by means of
a Fisher exact test for nominal variables and the Wilcoxon
test for continuous variables. 
The absolute increment in titer due to the first vaccina
tion was statistically significant for all three strains
(Figure 1A).
The seroprotection rates against A(H1N1), A(H3N2),
B/Yamagata and against all three viruses (total influenza
seroprotection) before/after the first vaccination were 19%
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Table 1. Patients’ characteristics. 
Total number of patients                                                         48
Gender                                                              male                               32
                                                                          female                             16
Age (years)                                                    median                             59
                                                                           range                           41-81
Immunomodulatory therapy                        none                              10
before 1st vaccination                               completed                         19
                                                                         ongoing                            19
Time from last immunomodulatory        median                             10
therapy to 1st vaccination (months)          range                          0- 78.5
Chemotherapy including bortezomib        none                               2
before 1st vaccination                                completed                         44
                                                                         ongoing                             2
Time from last chemotherapy,                 median                           19.4
including bortezomib, to 1st vaccination   range                        0.8- 103.7
(months)                                                               
Time from last autologous SCT                median                           28.1
to 1st vaccination (months)                          range                        2.7- 103.1
N. of autologous SCT                                        0                                    8
                                                                               1                                   14
                                                                               2                                   22
                                                                               3                                    4
Immunomodulatory therapy                        none                               30
within 2 months after 1st vaccination      initiated                             3
                                                                         ongoing                            15
Chemotherapy, including bortezomib,      none                               40
within 2 months after 1st  vaccination      initiated                             8
                                                                         ongoing                             0
International Staging System Score           none                                2
at therapy initiation                                           1                                   24
                                                                               2                                   11
                                                                               3                                    6
Cytogenetics at initiation                   1q21 > 3 copies                      8
of therapy                                                        t(4;14)                              4
                                                                          del17p                              4
                                                                   none of those                      24
                                                                     not analyzed                         7
Remission status at 1st vaccination            None                                1
                                                                              CR                                  8
                                                                             nCR                                 9
                                                                           VGPR                               6
                                                                              PR                                  9
                                                                             MR                                 1
                                                                              SD                                  3
                                                                              PD                                  8
                                                                  relapse without                     3
                                                                therapy indication                     
Durie & Salmon stage                                      IA                                 11
at the time of initial diagnosis                       IIA                                  4
                                                                              III                                  3
                                                                             IIIA                                25
                                                                             IIIB                                 4
SCT: stem cell transplantation. Response criteria (modified after Durie et al., 2006):
CR: complete remission; nCR: near complete remission; VGPR: very good partial
remission; PR: partial remission; MR: minor response; SD: stable disease; PD: pro-
gressive disease. 
(9/48)/40% (19/48), 13% (6/48)/35% (17/48), 10%
(5/48)/19% (9/48) and 0% (0/48)/15% (7/48), respectively. 
The improvement of seroprotection provided by the first
vaccination was statistically significant for A(H1N1),
A(H3N2) and for all strains taken together (Figure 1B). 
The corresponding seroconversion rates for A(H1N1),
A(H3N2), B/Yamagata and for all three antigens were 27%
(13/48), 34% (16/48), 6% (3/48), and 6% (3/48), respective-
ly (Figure 1B).  Except for shivering after the first vaccina-
tion, reported by one patient, no adverse events were
observed in any patient. 
Out of the remaining 40 patients who did not display
seroprotection after the first vaccination, one dropped out
for loss of follow-up, two underwent autologous stem cell
transplantation (SCT), five rejected a second vaccination
and eight did not receive a second dose for various logistic
reasons. The remaining 24 patients were given a second,
booster dose of vaccine. Subsequently, the absolute HI
titers increased significantly for all three antigens, com-
pared to pre-vaccination titers (Figure 1A). 
The cumulative seroprotection rates for A(H1N1),
A(H3N2), B/Yamagata and for all three antigens after the
second vaccination were 63% (30/48), 54% (26/48) 38%
(18/48), and 31% (15/48), respectively. Compared to the
frequency of seroprotection after the first vaccination, there
were significant improvements in seroprotection against all
strains and also against each single strain after the second
vaccination (Figure 1B). 
Cumulative seroconversion rates after the second vacci-
nation for A(H1N1), A(H3N2), B/Yamagata and for all three
antigens were 52% (25/48), 50% (24/48), 23% (11/48) and
17% (8/48), respectively. Seroconversion improved signifi-
cantly after the second vaccination (Figure 1B).
The seroprotection and seroconversion rates are summa-
rized in Table 2. 
The patients’ characteristics (Table 1) were analyzed for
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Table 2. Response to vaccination. 
Cumulative seroprotection
A(H1N1) A(H3N2) B/Yamagata All strains
Pre vacc 19% (9/48) 13% (6/48) 10% (5/48) 0% (0/48)
1st vacc 40% (19/48) 35% (17/48) 19% (9/48) 15% (7/48)
2nd vacc 63% (30/48) 54% (26/48) 38% (18/48) 31% (15/48)
Cumulative seroconversion
A(H1N1) A(H3N2) B/Yamagata All strains
1st vacc 27% (13/48) 34% (16/48) 6% (3/48) 6% (3/48)
2nd vacc 52% (25/48) 50% (24/48) 23% (11/48) 17% (8/48)
Upper panel: percentages and absolute numbers of patients displaying seroprotec-
tion against single influenza strains as well as total seroprotection before the first
vaccination and after the first and second vaccinations. Lower panel: percentages
and absolute numbers of patients who seroconverted in response to the first and sec-
ond vaccinations. 
Figure 1. (A) Antibody titers
against different influenza virus
strains after sequential vac-
cination in myeloma patients.
Box plots depict the increase of
antibody titers against the dif-
ferent influenza strains.
Differences of HI titers between
two time points were analyzed
using the signed-rank Wilcoxon
test. Statistically significant 
P-values are shown in the plots.
(B) Immune response to double
vaccination against seasonal
influenza. Bar charts depict
seroprotection (upper panel)
and seroconversion (lower
panel) rates before, after the
first and second vaccinations.
Differences were analyzed by
pairwise McNemar test. P-val-
ues are shown. 
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their impact on immunization results. Most of the tested
variables, including chemotherapy, immunomodulatory
therapy and number of autologous stem cell transplants,
did not show a significant association with seroprotection
or seroconversion rates after the first and second vaccina-
tions. Neither was the outcome after the first vaccination
different according to chemotherapy or immunomodulato-
ry therapy within the last 6 months or according to autol-
ogous SCT status. Differentiation according to the latter
mentioned variables was not feasible after the second vac-
cination because of small sample sizes.
The period of time from last autologous SCT to first vac-
cine was significantly longer in patients mounting A(H3N2)
seroprotection (median 18.9 versus 56.4 months; P=0.006)
as well as seroconversion of A(H3N2) titers (19.0 versus
56.2 months; P=0.01) and A(H1N1) titers (20.9 versus 37.6
months; P=0.04) after the first vaccination.
Only two of the 24 patients receiving a second vaccina-
tion had not undergone autologous SCT. Of those two, one
developed total seroprotection after the second vaccina-
tion. All 24 patients had received chemotherapy before the
first vaccination, and 20 had received or were being treated
with immunomodulatory therapy. Of four patients who
had not been treated with preceding immunomodulatory
therapy, two developed total protection after the second
vaccination.
Regarding DT titers, seroprotection against diphtheria
(P<0.001) and long-term protection against tetanus
(P=0.007) were found at significantly higher frequencies in
patients who also had total seroprotection against influen-
za after the second vaccination. Accordingly, anti-diphthe-
ria titers (P=0.0007) and anti-tetanus titers (P=0.02) were
significantly higher in patients with seroprotection against
all strains after the second vaccination. Remarkably, after
the first vaccination, no significant correlation between
seroprotection and recall antigen titers was detected. 
Similar results were found for seroconversion: in patients
who had seroconverted for all three influenza antigens
after the second vaccination (P=0.007), seroprotection
against diphtheria was significantly more frequent, and
anti-diphtheria titers were significantly higher in those
patients (P=0.02).
This pilot study suggests that a second vaccine dose may
boost the immune response against influenza in MM
patients. The frequency of total seroprotection was
increased from 15% after the first vaccination to 31% after
the second, booster dose. Likewise, the rate of overall sero-
conversion increased from 6% to 17%. The highest success
rates were achieved for A(H1N1), with seroprotection rates
of 40% and 63% and seroconversion rates of 27% and
52% after the first and second vaccinations, respectively. 
Improved immunization results against A(H1N1) as a
result of double vaccination have also been reported for
other immunocompromised hosts, e.g. patients positive for
human immunodeficiency virus (seroconversion rates of
68.2% and 91.9% after the first and second doses, respec-
tively)8 and hemodialysis patients (seroprotection rates of
64.1% and 88.6% after the first and second doses, respec-
tively).7
Double vaccination against A(H1N1) in patients after
allogeneic or autologous SCT9 improved the seroprotection
rate from 17.9% at baseline to 44.2% after the first vacci-
nation and to 48.8% after the second. Gueller et al. showed
seroconversion rates of A(H1N1) titers in SCT patients of
41.2% and 81.8% after the first and second vaccinations,
respectively.6
In our study, the interval from last SCT to first vaccine
was found to be associated with protective HI titers and
with seroconversion. This is in line with data from
Engelhard et al., who found a correlation between the time
from SCT to immunization and seroconversion in a popu-
lation of 48 SCT recipients (of whom only 13 were autolo-
gous graft recipients).10
In our analysis, no association with chemotherapy or
immunomodulatory treatment (thalidomide, lenalidomide,
interferon) was found. This was unexpected, as previous
studies suggested an adverse impact of chemotherapy,3,11
but a beneficial effect of immunomodulatory therapy12 on
vaccine effectiveness. Our finding may be due to the overall
low number of subjects in the study and the heterogeneity
of the population. 
Patients in our study who responded to prior DT vacci-
nation were more likely to respond adequately to the
influenza vaccination. Seroprotection against diphtheria
and long-term protection against tetanus were found signif-
icantly more frequently in patients who also had seropro-
tection against all three influenza antigens after the second
vaccination. 
Girndt et al. reported a strong relation of vaccination
responses to hepatitis B and tetanus toxoid in dialysis
patients.13 The response to tetanus and diphtheria vaccines
might serve as a convenient and informative marker for
assessing an impaired immune response to other vaccina-
tions. 
Double vaccination against influenza in MM patients
seems to enhance protection and should be systematically
studied. A larger and stratified cohort of patients would be
needed for systematic assessment of associations between
immunization results and clinical parameters. Furthermore,
clinical effectiveness should also be studied, particularly
with regards to the impact on influenza incidence, morbid-
ity and mortality.
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